Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Genome editing using clustered regularly interspersed short palindromic repeats (CRISPR) and CRISPR-associated proteins offers the potential to facilitate safe and effective treatment of genetic diseases refractory to other types of intervention. Here, we identify some of the major challenges for clinicians, regulators, and human research ethics committees in the clinical translation of CRISPR-mediated somatic cell therapy.

Original publication

DOI

10.1186/s13073-017-0475-4

Type

Journal article

Journal

Genome Med

Publication Date

25/09/2017

Volume

9

Keywords

Biomedical Technology, Cell- and Tissue-Based Therapy, Clinical Medicine, Clustered Regularly Interspaced Short Palindromic Repeats, Humans, Intellectual Property